Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMPEL NEUROPHARMA, INC.

(IMPL)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 09/20 11:30:22 am
13.505 USD   -6.48%
09/15IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $39 From $37, Maintains Outperform Rating
MT
09/10Health Care Stocks Ail During Friday Trading
MT
09/10Health Care Stocks Ailing Friday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IMPEL NEUROPHARMA INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities (form 8-K)

07/07/2021 | 07:33am EDT

Item 1.01. Entry into a Material Definitive Agreement.

On July 2, 2021, (the "Effective Date"), Impel NeuroPharma, Inc. (the "Company") entered into a loan and security agreement (the "Agreement") with Oxford Finance LLC ("Oxford"), as the collateral agent and a lender, and Silicon Valley Bank, as a lender (together with Oxford, the "Lenders"), pursuant to which the Lenders have agreed to lend the Company up to an aggregate of $50.0 million in a series of term loans (the "Term Loan").

Upon entering into the Agreement, the Company borrowed $20.0 million from the Lenders (the "Term A Loan"), with approximately $10.76 million of such amount applied to the repayment of the outstanding principal, interest and final payment fees owed pursuant to the Company's prior loan and security agreement dated November 5, 2020.

Under the terms of the Agreement, the Company may, at its sole discretion, borrow from the Lenders up to an additional $10.0 million (the "Term B Loan") upon the achievement by the Company of NDA approval from the Federal Drug Administration of INP104, as determined by Oxford in its sole and absolute discretion (the "Term B Milestone Event"). The Company may draw the Term B Loan during the period commencing on the date of the occurrence of the Term B Milestone Event and ending on the earliest of (i) September 30, 2021 (ii) the sixtieth (60th) day following the occurrence of the Term B Milestone Event, and (iii) the occurrence of an event of default.

Under the terms of the Agreement, the Company may, at its sole discretion, borrow from the Lenders up to an additional $20.0 million (the "Term C Loan") upon the achievement by the Company of net revenue for a trailing six (6) month period of at least $15,000,000, as determined by Oxford in its sole and absolute discretion (the "Term C Milestone Event"). The Company may draw the Term C Loan during the period commencing on the date of the occurrence of the Term C Milestone Event and ending on the earliest of (i) December 31, 2022 (ii) the sixtieth (60th) day following the occurrence of the Term C Milestone Event, and (iii) the occurrence of an event of default.

The proceeds from the Term Loans under the Agreement may be used to satisfy the Company's future working capital needs and to fund its general business requirements. The Company's obligations under the Agreement are secured by all assets of the Company, other than its intellectual property. The Company has also agreed not to encumber its intellectual property assets, except as permitted by the Agreement.

All of the Term Loans mature on July 1, 2026 (the "Maturity Date") and will be interest-only through September 1, 2023, provided however, that following Company's achievement of the Term C Milestone Event by not later than December 31, 2022, the Term Loans will be interest-only through September 1, 2024, followed by 35 equal monthly payments of principal and interest, provided, however, that following Company's achievement of the Term C Milestone Event by no later than December 31, 2022, such number of months shall be automatically reduced to 23 consecutive months. The Term Loans will bear interest at a floating per annum rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the greater of (1) the thirty (30) day U.S. LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (2) 0.11%, plus (b) 7.84%.

The Company will be required to make a final payment of 6.5% of the original principal amount of the Term Loans drawn, payable on the earlier of (i) the Maturity Date, (ii) the acceleration of any Term Loans, or (iii) the prepayment of the Term Loans (the "Final Payment"). The Company may prepay all, but not less than all, of the Term Loans upon 30 days' advance written notice to Oxford, provided that the Company will be obligated to pay a prepayment fee equal to (i) 3.0% of the principal amount of the applicable Term Loan prepaid on or before the first anniversary of the applicable funding date, (ii) 2.0% of the principal amount of the applicable Term Loan prepaid between the first and second anniversary of the applicable funding date, and (iii) 1.0% of the principal amount of the applicable Term Loan prepaid thereafter, and prior to the Maturity Date (each, a "Prepayment Fee").

The Agreement contains customary affirmative and restrictive covenants, including covenants regarding incurrence of additional indebtedness or liens, investments, transactions with affiliates, delivery of financial statements, maintenance of inventory, payment of taxes, maintenance of insurance, protection of intellectual property rights, dispositions of property, business combinations or acquisitions, among other customary covenants. The Company is also restricted from paying dividends or making other distributions or payments on its capital stock, subject to limited exceptions. In the event that the Company borrowers the Term C Loan, the Company will be subject to a quarterly minimum net revenue financial covenant. The Agreement provides that an event of default will occur if, among other triggers, there occurs any circumstances that could reasonably be expected to result in a material adverse change in the business, or operations or condition (financial or otherwise) of the Company or a material impairment of the prospect of the Company to repay any portion of its obligations under the Agreement. The Agreement also includes customary representations and warranties, other events of default and termination provisions.

In connection with entering into the Agreement and borrowing the Term A Loan, the Company issued to the Lenders warrants exercisable for an aggregate of 71,522 shares of the Company's common stock (the "Warrants"). The Warrants are exercisable in

--------------------------------------------------------------------------------

whole or in part, immediately, and have a per share exercise price of $8.389, which is the 10-trading day trailing average closing price prior to the date of the Term A Loan funding. The Warrants will terminate on the earlier of July 2, 2031 or the closing of certain merger or consolidation transactions. If the Company borrows additional Term Loans under the Agreement, the Company will be required to issue to the Lenders additional warrants exercisable for a number of shares of the Company's common stock equal to 3.0% of the total additional Term Loans funded by the Lenders divided by the lower of (x) the 10-trading day trailing average closing price prior to such Term Loan funding or (y) the closing price on the day prior to such Term Loan funding.

The foregoing is only a summary of the material terms of the Agreement and the Warrants, and does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement and the Warrants, which will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 above is hereby incorporated by reference into Item 2.03.

Item 3.02. Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 above that relates to the issuance of the Warrants is hereby incorporated by reference into Item 3.02.

The Warrants described in Item 1.01 above were offered and sold in reliance upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the "Securities Act"), in that the issuance of the Warrants did not involve a public offering.




Item 9.01 Exhibits.


(d) Exhibits




Exhibit No.                                  Description

99.1               Press release issued by Impel NeuroPharma, Inc. regarding a $50
                 million debt financing agreement with Oxford Finance LLC and Silicon
                 Valley Bank  .
104              Cover Page Interactive Data File (embedded within the Inline XBRL
                 document)







--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about IMPEL NEUROPHARMA, INC.
09/15IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $39 From $37, Mainta..
MT
09/10Health Care Stocks Ail During Friday Trading
MT
09/10Health Care Stocks Ailing Friday
MT
09/10Wall Street Set for Gains as Biden-Xi Call Lifts Sentiment
MT
09/10IMPEL NEUROPHARMA : Prices Offering at $15 Per Share
MT
09/09IMPEL NEUROPHARMA : Announces Pricing of $45.0 Million Public Offering
AQ
09/09IMPEL NEUROPHARMA : Shares Rebound Amid Heavy Trading
MT
09/08WALL STREET STOCK EXCHANGE : Wall Street bogged down by Delta spread
09/08ANALYST RECOMMENDATIONS : Adobe, Broadcom, Chipotle Mexican Grill, Netflix, Voda..
09/07IMPEL NEUROPHARMA : Launches Stock Offering
MT
More news
Analyst Recommendations on IMPEL NEUROPHARMA, INC.
More recommendations